| Aug 2 |
Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?
|
| Jul 1 |
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
|
| Jun 28 |
Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
|
| Jun 28 |
FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
|
| Jun 28 |
Rocket falls as FDA rejects gene therapy Kresladi
|
| Jun 28 |
Rocket gene therapy rejected by FDA over manufacturing
|
| Jun 28 |
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
|
| Jun 5 |
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
|
| May 31 |
Rocket Pharmaceuticals (NASDAQ:RCKT) Is In A Good Position To Deliver On Growth Plans
|
| May 30 |
EC grants orphan medicinal product status to Rocket’s RP-A601
|
